Bayer secures FDA filing acceptance. Bayer stock gains 1.61 percent

Published on 10/14/2026 at 12:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA accepted Bayer's Finerenon filing on October 8, 2026 for a kidney indication. Bayer stock costs EUR 44.86 on October 14, 2026 versus the EUR 44.15 Xetra close.

Pipeline and earnings checkpoints

FDA accepted Bayer's Finerenon filing on October 8, 2026.
Second-quarter sales rose 2.20 percent to EUR 10.87 billion.
Bayer stock trades at EUR 44.86 at 12:47 p.m. CEST at Lang & Schwarz on October 14, 2026, 1.61 percent above the Xetra close of October 13, 2026.
JPMorgan kept its EUR 61.00 target and Overweight rating on October 1, 2026.

Börsen-Editorial: Handelsraum mit großen LED-Bildschirmen, DAX-Candlestick-Chart in Grün, im Vordergrund ein Pillenflakon mit weißen Tabletten neben einer Tastatur — Trading-Floor mit DAX-Kursanzeige auf Großbildschirm, Tablettenflakon im Vordergrund, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) secured a regulatory step for Finerenon as its stock traded at EUR 44.86 at Lang & Schwarz on October 14, 2026 at 12:47 p.m. CEST, up EUR 0.71 or 1.61 percent versus the Xetra close of October 13, 2026. Bayer said on October 8, 2026 that the U.S. Food and Drug Administration had accepted its filing for a further Finerenon indication in chronic kidney disease without diabetes.

FDA filing adds pipeline context

The filing is based on positive Phase III FIND-CKD results and seeks to expand the use of Finerenon beyond its existing indications, according to Bayer on October 8, 2026. The company operates across Pharmaceuticals, Crop Science and Consumer Health, but the filing puts the near-term investor focus on pharmaceutical pipeline execution.

What does the next quarter test?

Bayer's second-quarter sales rose 2.20 percent to EUR 10.87 billion, while EBITDA before special items increased 1.90 percent to EUR 2.14 billion, according to Bayer in its August 4, 2026 investor release. Those figures give the upcoming report a measurable benchmark rather than leaving the pipeline story detached from operating performance.

Three dated Bayer developments: On September 17, 2026, the FDA approved Finerenon for a new indication in chronic kidney disease associated with Type 1 diabetes, according to Bayer. On October 2, 2026, Bayer announced a USD 2.20 billion investment in a new Ohio production site, the same investor-news page reported. On October 8, 2026, the FDA accepted the additional Finerenon filing.

Analyst caution meets a EUR 61 target

FinanzNachrichten reported on October 1, 2026 that JPMorgan kept its Overweight rating and EUR 61.00 price target. Analyst Richard Vosser cautioned that early expectations for the third quarter might be too high because of timing effects in agriculture, while full-year estimates were expected to remain broadly unchanged.

Next reporting date is November 3

Bayer will publish its third-quarter 2026 results on November 3, 2026 at 7:30 a.m. CET, followed by an investor call at 2:00 p.m. CET, according to Bayer. The timing makes the third-quarter figures the next test of whether the second-quarter growth rates can continue.

Stock trades above the Xetra close

Bayer's market capitalization was EUR 44.0 billion on October 14, 2026, while its 52-week range was EUR 25.78 to EUR 53.92. The current quote sits below the upper end of that range, leaving the November report and the Finerenon development as the clearest dated reference points for the stock.

The further course of trading is shown by the continuously updated real-time quote of Bayer stock.